Download z6o002142657st1_supp_mat_FINAL

Supplemental Materials
A Meta-Analysis of Cognitive Impairment Following Adult Cancer Chemotherapy
by O. C. Lindner et al., 2014, Neuropsychology
http://dx.doi.org/10.1037/neu0000064
Table S1
Characteristics of Articles Included in the Meta-Analysis of Chemotherapy-Induced Changes in Adults (n=44)
No.
1
Article
Therapy
Cancer(N)/Age (m)
Evaluation
Design
Study quality
(Ahles & Saykin,
Cyclophosphamide,
Treated with chemotherapy (breast
5 years post-
Cross-
23
2002)
methotrexate,
cancer = 35; lymphoma = 36).
diagnosis
sectional
flouracil,
Without chemotherapy (breast=35;
vincristine,
lymphoma=22)
doxorubicin,
Age=56
prednisone,
etoposide,
carboplatin,
procarbazine,
bleomycin, etc.
2
(Ahles et al., 2003)
Cyclophosphamide,
Breast cancer (51)
4-12 years post-
Cross-
methotrexate,
Lymphoma (29)
treatment
sectional
flouracil,
Age=55.8
24
doxorubicin,
vincristine,
prednisone,
vinblastine,
thiotepa, halotestin,
carboplatin, taxol.
3
(Castellon et al.,
Cyclophosphamide,
Breast cancer with chemotherapy
2-5 years post-
Cross-
2004)
methotrexate,
(36)
treatments
sectional
flouracil,
Breast cancer without
doxorubicin, taxane,
chemotherapy (17)
27
tamoxifen.
Healthy group (19)
Age=48.1
4
(Collins, Mackenzie,
Flouracil,
Breast cancer with chemotherapy
Stewart, Bielajew, &
epirubicin,
(53)
Verma, 2009)
cyclophosphamide,
Breast cancer without
doxorubicin,
chemotherapy (40)
cisplatin, taxols,
Age=57.7
1 year
Longitudinal
25
Longitudinal
24
23
hormonal therapy.
5
(Debess, Riis,
Cyclophosphamide,
Breast cancer with chemotherapy
Pre-treatment
Engebjerg, & Ewertz,
epirubicin, flouracil,
(75)
4 weeks post-
2010)
tamoxifen.
With tamoxifen (26)
treatment
Without chemotherapy (19)
Healthy controls (208)
Age=50.3
6
(Deprez et al., 2010)
Flouracil,
Breast cancer with chemotherapy
80-160 days post-
Cross-
epirubicin,
(17)
chemotherapy
sectional
cyclophosphamide,
Without chemotherapy (10)
taxol, tamoxifen.
Healthy controls (18)
Age=44.5
7
(de Ruiter et al.,
Cyclophosphamide,
Breast cancer with chemotherapy
10 years post-
Cross-
21
2010)
thiotepa,
(19)
treatment
sectional
carboplatin,
Without chemotherapy (15)
flouracil, epirubicin,
Age=57.2
Younger patients (59). Age=45
Pre-treatment
Mixed
19
Older patients (71). Age=69.1
After first course
Hematological or gastrointestinal
of chemotherapy
malignancy
(2-8 days after
Mixed
19
tamoxifen
8
(Eberhardt et al.,
Not reported
2006a)
first
chemotherapy)
9
(Eberhardt et al.,
2006b)
Not reported
Younger patients (43). Age=44.3
Pre-treatment
Older patients (34). Age=68.9
6 months after the
Hematological or gastrointestinal
start of treatment
malignancy
10
(Harder et al., 2002)
Cyclophosphamide,
Hematological malignancies (40)
22-82 months
Cross-
cytosine, etoposide,
Age=40.8
post-bone marrow
sectional
total body
19
transplant
irradiation
11
(Hedayati,
Flouracil,
Breast cancer with chemotherapy
Pre-diagnosis,
Alinaghizadeh,
epirubicin,
(18)
post-surgery, pre-
Schedin, Nyman, &
cyclophosphamide,
With hormone therapy (45)
adjuvant
Albertsson, 2012)
doxetaxel,
No chemotherapy (14)
treatment, 6
doxorubicin,,
Healthy controls (69)
months into
hormonal treatment.
Age=56
treatment, 3
Mixed
24
Longitudinal
30
months posttreatment
12
(Hermelink et al.,
Epirubicin,
Breast cancer pre-treatment (109)
Pre-treatment
2007)
paclitaxel,
Post-treatment (101)
Towards the end
cyclophosphamide,
Age=48.6
of treatment
methotrexate,
(21days-6months
flouracil,
later)
darbepoetin α.
13
(Hess et al., 2010)
Not reported
Ovarian cancer pre-treatment (27)
Pre-treatment
3rd course (26)
3rd course
6th course (23)
6th course
Longitudinal
23
Longitudinal
27
Mixed
26
Age=59.3
14
(Hurria et al., 2006)
Cyclophosphamide,
Breast cancer pre-treatment (31)
Pre-treatment
methotrexate,
Post-treatment (28)
6 months post-
flouracil,
Age= 71
treatment
Mixed cancers: breast, colorectal,
Pre-treatment
doxorubicin ,
paclitaxel,
trastumab,
hormonal therapy.
15
(Iconomou et al.,
Not reported apart
2008)
from epoetin alfa.
lung, genitourinary, other (50).
12 week later
Age=58.9
16
(Inagaki et al., 2007)
Doxorubicin,
One year study:
1 and 3 years
cyclophosphamide,
Breast cancer with chemotherapy
post-treatment
methotrexate,
(51)
flouracil, epirubicin,
Breast cancer without
paclitaxel,
chemotherapy (55)
doxifluridine,
Healthy controls (55)
carmogur,
Three year study:
tegafur/uracil,
With chemotherapy (73)
hormonal and
Without chemotherapy (59)
radiation therapy.
Healthy controls (37)
Mixed
24
Longitudinal
27
Age=47.4
17
(Jacobsen et al., 2004)
Carboplatin,
Ovarian, lung, breast, endometrial,
Pre-treatment
paclitaxel,
other cancer (77)
Before fourth
doxorubicin,
Age=60
treatment cycle
cisplatin, docetaxel,
etoposide,
gemcitabine,
cyclophosphamide,
and others.
18
(Jansen, Dodd,
Doxorubicin,
Breast cancer pre-treatment (32)
Pre-treatment
Miaskowski,
cyclophosphamide.
Post-treatment (30)
1 week post-
Age=49.6
treatment
Dowling, & Kramer,
2008)
Longitudinal
27
Longitudinal
28
6 months posttreatment
19
(Jansen, Cooper,
Doxorubicin,
Breast cancer pre-treatment (71)
Pre-treatment
Dodd, & Miaskowski,
cyclophosphamide,
2 weeks post-chemotherapy (66)
2 week post-
2010)
taxane.
1 week post-taxane (42)
chemotherapy
6 months post-treatment (67)
1 week post-
Age=50.3
taxane
6 months post-
treatment
20
(Jenkins et al., 2006)
Flouracil,
Breast cancer with chemotherapy
Pre-treatment
Mixed
24
epirubicin,
(85)
6 months post-
cyclophosphamide,
With hormonal/radiotherapy (43)
treatment
methotrexate,
Healthy controls (49)
18 months post-
doxorubicin,
Age=54.10
treatment
Doxorubicin,
Ductal carcinoma or breast cancer
6 months post-
Cross-
24
cyclophosphamide,
(187)
treatment
sectional
doxetaxel,
Healthy controls (187)
paclitaxel,
Age=41-61
paclitaxel.
21
(Jim et al., 2009)
methotrexate,
flouracil, epirubicin;
hormonal treatment.
22
(Kesler, Bennett,
Cyclophosphamide,
Breast cancer (14)
6 months post-
Cross-
Mahaffey, & Spiegel,
methotrexate,
Healthy controls (14)
treatment
sectional
21
2009)
flouracil,
Age=54.6
doxorubicin, taxol.
23
24
(Kreukels et al., 2005)
(Kreukels et al., 2006)
Cyclophosphamide,
Breast cancer with chemotherapy
3-5 years post-
Cross-
methotrexate,
(26)
treatment
sectional
flouracil, tamoxifen,
Without chemotherapy (23)
radiotherapy.
Age=52.3
Cyclophosphamide,
Breast cancer high dose (17)
4 years post-
Cross-
thiotepa,
Standard dose (23)
treatment
sectional
carboplatin,
No chemotherapy (39)
etoposide, flouracil,
Age=51.9
Mixed
23
23
tamoxifen,
radiotherapy
25
(Mehlsen, Pedersen,
Cyclophosphamide,
Breast cancer (34)
Pre-treatment
Jensen, & Zachariae,
epirubicin, flouracil,
Cardiac patients (12)
2-6 weeks post-
2009)
tamoxifen.
Healthy controls (12)
treatment
Age=46.1
Cardiac: 3 months
23
later
Controls: 12-16
weeks later
26
(Meyers, Byrne, &
Cisplatin,
Small cell lung cancer with
Pre-treatment
Cross-
Komaki, 1995)
ifosfamide,
chemotherapy (25)
group
sectional
etoposide,
Without chemotherapy (21)
Post-treatment
radiotherapy
Age=54.8
and before cranial
23
irradiation group.
27
(Pedersen et al., 2009)
Bleomycin,
Testicular cancer chemotherapy
2-7 years post-
Cross-
etoposide, cisplatin,
(36)
treatment
sectional
radiotherapy
No chemotherapy (36)
Mixed
24
Age=40.1
28
(Quesnel, Savard, &
Doxorubicin,
Breast cancer chemotherapy (41)
Pre-chemotherapy
Ivers, 2009)
cyclophosphamide,
No chemotherapy (40)
Pre-radiotherapy
flouracil, etoposide,
Age=52.7
Post-treatment
taxotere, hormonal
(34-38 days)
26
therapy
3 months followup
29
30
31
(Reid-Arndt, Hsieh, &
Doxorubicin,
Breast cancer:
6 months post-
Perry, 2010)
cyclophosphamide,
6 months (39)
treatment
paclitaxel, taxotere
12 months (33)
12 months post-
Age=53.3
treatment
Cyclophosphamide,
Breast cancer with chemotherapy
methotrexate,
(39)
flouracil, tamoxifen.
No chemotherapy (34)
radiotherapy
Age= 46.6
(Scheibel, Valentine,
Interferon alpha,
O'Brien, & Meyers,
2004)
(Schagen et al., 1999)
Longitudinal
21
2 years post-
Cross-
24
treatment
sectional
Chronic myelogenous leukemia
Pre-treatment
Longitudinal
22
cytosine
(30)
14-43 weeks
arabinoside,
Age=46
within treatment
24
hydroxyurea
32
(Scherwath et al.,
Epirubicin,
Breast cancer with chemotherapy
5 years post-
Cross-
2006)
cyclophosphamide,
(47)
treatment
sectional
methotrexate,
Without chemotherapy (29)
flouracil, thiotepa,
Age=53.2
mitoxantrone,
tamoxifen
33
34
(Schilder et al., 2009)
Doxorubicin,
Breast cancer with chemotherapy
2 years post-
Cross-
28
cyclophosphamide,
(80)
treatment
sectional
tamoxifen,
Healthy controls (48)
exemestane
Age=58.8
(Shilling, Jenkins,
Flouracil, etoposide,
Breast cancer with chemotherapy
Pre-treatment
Mixed
27
Morris, Deutsch, &
cyclophosphamide,
(50)
6 months post-
Bloomfield, 2005)
methotrexate,
Healthy controls (43)
treatment
doxorubicin,
Age=51.7
25
docetaxel
35
(Small et al., 2011)
Doxorubicin,
Breast cancer with chemotherapy
6 months post-
Cross-
cyclophosphamide,
(72)
treatment
sectional
methotrexate,
Without chemotherapy (58)
taxane, flouracil
Healthy controls (204)
Age=55.07
36
(Stewart et al., 2008)
Flouracil,
Breast cancer with chemotherapy
Pre-treatment
epirubicin,
(61)
2 months post-
cyclophosphamide,
Without chemotherapy (51)
treatment
doxorubicin,
Age=57.7
Mixed
27
Mixed
25
Cross-
24
cisplatin, taxol,
hormonal therapy
37
(Tager et al., 2010)
Doxorubicin,
Ductal carcinoma or breast cancer
Pre-treatment
cyclophosphamide,
with chemotherapy (30)
1 months post-
docetaxel/paclitaxel,
Without chemotherapy (31)
treatment
cytoxan,
Age=60.7
6 months post-
methotrexate,
treatment
flouracil, hormonal
therapy
38
(van Dam et al., 1998)
Cyclophosphamide,
Breast cancer with chemotherapy
2 years post-
epirubicin, flouracil,
(70)
thiotepa,
Without chemotherapy (34)
carboplatin,
Age=46.5
treatment
sectional
Mixed
28
Longitudinal
29
Longitudinal
25
radiotherapy
39
(Vearncombe et al.,
Flouracil,
Breast cancer with chemotherapy
Pre-treatment
2009)
epirubicin,
(138)
1 month post-
cyclophosphamide,
Without chemotherapy (21)
treatment
doxorubicin,
Age=49.3
methotrexate, taxol,
taxotere.
40
41
(Wefel, Lenzi,
Flouracil,
Breast cancer (18)
Pre-treatment
Theriault, Davis, &
doxorubicin,
Age=45.4
3 weeks post-
Meyers, 2004)
cyclophosphamide,
treatment
methotrexate,
12 months post-
vinblastine
treatment
(Wefel, Saleeba,
Flouracil,
Breast cancer (42)
Pre-treatment
Buzdar, & Meyers,
doxorubicin,
Age=48.8
2 months post-
2010)
cyclophosphamide,
treatment
paclitaxel,
7 months post-
radiotherapy
treatment
13 months posttreatment
42
(Whitney et al., 2008)
Cisplatin, etoposide,
Non-small cell lung cancer (14)
Pre-treatment
radiotherapy
Age= 60.2
1 and 7 months
Longitudinal
24
20
post-treatment
43
(Wieneke & Dienst,
Cyclophosphamide,
Breast cancer (28)
0.5 – 12 months
Cross-
1995)
methotrexate,
Age= 42
post-treatment.
sectional
flouracil,
doxorubicin,
tamoxifen
44
(Yoshikawa et al.,
Cyclophosphamide,
Breast cancer with chemotherapy
Assessed 3 years
Cross-
2005)
methotrexate,
(44)
post-treatment
sectional
11
flouracil,
Without chemotherapy (31)
tegafur/uracil,
Age=48.2
doxorubicin,
doxifluridine,
carmofur,
tamoxifen,
radiotherapy
References
Abstracts of the 9th World Congress of Psycho-Oncology, hosted by the International
Psycho-Oncology Society (IPOS), September 16–20, 2007, London, United Kingdom.
(2007). Psycho-Oncology, 16(9), S1–S1.
Abstracts of the IPOS 11th World Congress of Psycho-Oncology, June 21–25, 2009, Vienna,
Austria. (2009). Psychooncology, 18 Suppl 2, S1–S340.
Abstracts of the IPOS 12th World Congress of Psycho-Oncology, May 25–29, 2010, Quebec
City, QC, Canada. (2010). Psychooncology, 19 Suppl 2, S1–S325.
Abstracts of the IPOS 13th World Congress of Psycho-Oncology, October 16–20, 2011,
Antalya, Turkey. (2011). Psychooncology, 20 Suppl 1, 1–308.
Ahles, T. A., & Saykin, A. J. (2002). Breast cancer chemotherapy-related cognitive
dysfunction. Clinical Breast Cancer, 3 Suppl 3, S84–S90.
Ahles, T. A., Saykin, A. J., Noll, W. W., Furstenberg, C. T., Guerin, S., Cole, B., et al. (2003).
The relationship of APOE genotype to neuropsychological performance in long-term
cancer survivors treated with standard dose chemotherapy. Psycho-Oncology, 12(6),
612–619.
Castellon, S. A., Ganz, P. A., Bower, J. E., Petersen, L., Abraham, L., & Greendale, G. A.
(2004). Neurocognitive performance in breast cancer survivors exposed to adjuvant
chemotherapy and tamoxifen. Journal of Clinical and Experimental Neuropsychology,
26(7), 955–969.
Collins, B., Mackenzie, J., Stewart, A., Bielajew, C., & Verma, S. (2009). Cognitive effects
of chemotherapy in post-menopausal breast cancer patients 1 year after treatment.
Psychooncology, 18(2), 134–143.
Debess, J., Riis, J. O., Engebjerg, M. C., & Ewertz, M. (2010). Cognitive function after
adjuvant treatment for early breast cancer: a population-based longitudinal study.
Breast Cancer Research and Treatment, 121(1), 91–100.
Deprez, S., Amant, F., Yigit, R., Porke, K., Verhoeven, J., Van den Stock, J., et al. (2010).
Chemotherapy-induced structural changes in cerebral white matter and its correlation
with impaired cognitive functioning in breast cancer patients. Human Brain Mapping.
de Ruiter, M. B., Reneman, L., Boogerd, W., Veltman, D. J., van Dam, F. S., Nederveen, A.
J., et al. (2010). Cerebral hyporesponsiveness and cognitive impairment 10 years after
chemotherapy for breast cancer. Human Brain Mapping.
Eberhardt, B., Dilger, S., Musial, F., Wedding, U., Weiss, T., & Miltner, W. H. (2006a).
Medium-term effects of chemotherapy in older cancer patients. Support Care Cancer,
14(3), 216–222.
Eberhardt, B., Dilger, S., Musial, F., Wedding, U., Weiss, T., & Miltner, W. H. (2006b).
Short-term monitoring of cognitive functions before and during the first course of
treatment. Journal of Cancer Research and Clinical Oncology, 132(4), 234–240.
Harder, H., Cornelissen, J. J., Van Gool, A. R., Duivenvoorden, H. J., Eijkenboom, W. M. H.,
& van den Bent, M. J. (2002). Cognitive functioning and quality of life in long-term
adult survivors of bone marrow transplantation. Cancer, 95(1), 183–192.
Hedayati, E., Alinaghizadeh, H., Schedin, A., Nyman, H., & Albertsson, M. (2012). Effects
of adjuvant treatment on cognitive function in women with early breast cancer.
European Journal of Oncology Nursing, 16(3), 315–322.
Hermelink, K., Untch, M., Lux, M. P., Kreienberg, R., Beck, T., Bauerfeind, I., et al. (2007).
Cognitive function during neoadjuvant chemotherapy for breast cancer: results of a
prospective, multicenter, longitudinal study. Cancer, 109(9), 1905–1913.
Hess, L. M., Chambers, S. K., Hatch, K., Hallum, A., Janicek, M. F., Buscema, J., et al.
(2010). Pilot study of the prospective identification of changes in cognitive function
during chemotherapy treatment for advanced ovarian cancer. Journal of Supportive
Oncology, 8(6), 252–258.
Hurria, A., Rosen, C., Hudis, C., Zuckerman, E., Panageas, K. S., Lachs, M. S., et al. (2006).
Cognitive function of older patients receiving adjuvant chemotherapy for breast
cancer: A pilot prospective longitudinal study. Journal of the American Geriatrics
Society, 54(6), 925–931.
Iconomou, G., Koutras, A., Karaivazoglou, K., Kalliolias, G. D., Assimakopoulos, K.,
Argyriou, A. A., et al. (2008). Effect of epoetin alfa therapy on cognitive function in
anaemic patients with solid tumours undergoing chemotherapy. European Journal of
Cancer Care, 17(6), 535–541.
Inagaki, M., Yoshikawa, E., Matsuoka, Y., Sugawara, Y., Nakano, T., Akechi, T., et al.
(2007). Smaller regional volumes of brain gray and white matter demonstrated in
breast cancer survivors exposed to adjuvant chemotherapy. Cancer, 109(1), 146–156.
Jacobsen, P. B., Garland, L. L., Booth-Jones, M., Donovan, K. A., Thors, C. L., Winters, E.,
et al. (2004). Relationship of hemoglobin levels to fatigue and cognitive functioning
among cancer patients receiving chemotherapy. Journal of Pain and Symptom
Management, 28(1), 7–18.
Jansen, C. E., Dodd, M. J., Miaskowski, C. A., Dowling, G. A., & Kramer, J. (2008).
Preliminary results of a longitudinal study of changes in cognitive function in breast
cancer patients undergoing chemotherapy with doxorubicin and cyclophosphamide.
Psycho-Oncology, 17(12), 1189–1195.
Jansen, C. E., Cooper, B. A., Dodd, M. J., & Miaskowski, C. A. (2010). A prospective
longitudinal study of chemotherapy-induced cognitive changes in breast cancer
patients. Support Care Cancer.
Jenkins, V., Shilling, V., Deutsch, G., Bloomfield, D., Morris, R., Allan, S., et al. (2006). A
3-year prospective study of the effects of adjuvant treatments on cognition in women
with early stage breast cancer. British Journal of Cancer, 94(6), 828–834.
Jim, H. S., Donovan, K. A., Small, B. J., Andrykowski, M. A., Munster, P. N., & Jacobsen, P.
B. (2009). Cognitive functioning in breast cancer survivors: a controlled comparison.
Cancer, 115(8), 1776–1783.
Kesler, S. R., Bennett, F. C., Mahaffey, M. L., & Spiegel, D. (2009). Regional brain
activation during verbal declarative memory in metastatic breast cancer. Clinical
Cancer Research, 15(21), 6665–6673.
Kreukels, B. P. C., Schagen, S. B., Ridderinkhof, K. R., Boogerd, W., Hamburger, H. L., &
van Dam, F. S. A. M. (2005). Electrophysiological correlates of information
processing in breast-cancer patients treated with adjuvant chemotherapy. Breast
Cancer Research and Treatment, 94(1), 53–61.
Kreukels, B. P. C., Schagen, S. B., Ridderinkhof, K. R., Boogerd, W., Hamburger, H. L.,
Muller, M. J., et al. (2006). Effects of high-dose and conventional-dose adjuvant
chemotherapy on long-term cognitive sequelae in patients with breast cancer: An
electrophysiologic study. Clinical Breast Cancer, 7(1), 67–78.
Mehlsen, M., Pedersen, A. D., Jensen, A. B., & Zachariae, R. (2009). No indications of
cognitive side-effects in a prospective study of breast cancer patients receiving
adjuvant chemotherapy. Psycho-Oncology, 18(3), 248–257.
Meyers, C. A., Byrne, K. S., & Komaki, R. (1995). Cognitive deficits in patients with smallcell lung-cancer before and after chemotherapy. Lung Cancer, 12(3), 231–235.
Pedersen, A. D., Rossen, P., Mehlsen, M. Y., Pedersen, C. G., Zachariae, R., & von der
Maase, H. (2009). Long-term cognitive function following chemotherapy in patients
with testicular cancer. Journal of the International Neuropsychological Society, 15(2),
296–301.
Quesnel, C., Savard, J., & Ivers, H. (2009). Cognitive impairments associated with breast
cancer treatments: results from a longitudinal study. Breast Cancer Research and
Treatment, 116(1), 113–123.
Reid-Arndt, S. A., Hsieh, C., & Perry, M. C. (2010). Neuropsychological functioning and
quality of life during the first year after completing chemotherapy for breast cancer.
Psychooncology, 19(5), 535–544.
Schagen, S. B., van Dam, F. S., Muller, M. J., Boogerd, W., Lindeboom, J., & Bruning, P. F.
(1999). Cognitive deficits after postoperative adjuvant chemotherapy for breast
carcinoma. Cancer, 85(3), 640–650.
Scheibel, R. S., Valentine, A. D., O'Brien, S., & Meyers, C. A. (2004). Cognitive dysfunction
and depression during treatment with interferon-alpha and chemotherapy. Journal of
Neuropsychiatry and the Clinical Neurosciences, 16(2), 185–191.
Scherwath, A., Mehnert, A., Schleimer, B., Schirmer, L., Fehlauer, F., Kreienberg, R., et al.
(2006). Neuropsychological function in high-risk breast cancer survivors after stemcell supported high-dose therapy versus standard-dose chemotherapy: evaluation of
long-term treatment effects. Annals of Oncology, 17(3), 415–423.
Schilder, C. M., Eggens, P. C., Seynaeve, C., Linn, S. C., Boogerd, W., Gundy, C. M., et al.
(2009). Neuropsychological functioning in postmenopausal breast cancer patients
treated with tamoxifen or exemestane after AC-chemotherapy: cross-sectional
findings from the neuropsychological TEAM-side study. Acta Oncologica, 48(1), 76–
85.
Shilling, V., Jenkins, V., Morris, R., Deutsch, G., & Bloomfield, D. (2005). The effects of
adjuvant chemotherapy on cognition in women with breast cancer--preliminary results
of an observational longitudinal study. Breast, 14(2), 142–150.
Small, B. J., Rawson, K. S., Walsh, E., Jim, H. S., Hughes, T. F., Iser, L., et al. (2011).
Catechol-O-methyltransferase genotype modulates cancer treatment-related cognitive
deficits in breast cancer survivors. Cancer, 117(7), 1369–1376.
Stewart, A., Collins, B., Mackenzie, J., Tomiak, E., Verma, S., & Bielajew, C. (2008). The
cognitive effects of adjuvant chemotherapy in early stage breast cancer: a prospective
study. Psychooncology, 17(2), 122–130.
Tager, F. A., McKinley, P. S., Schnabel, F. R., El-Tamer, M., Cheung, Y. K., Fang, Y., et al.
(2010). The cognitive effects of chemotherapy in post-menopausal breast cancer
patients: a controlled longitudinal study. Breast Cancer Research and Treatment,
123(1), 25–34.
van Dam, F. S. A. M., Schagen, S. B., Muller, M. J., Boogerd, W., von der Wall, E., Fortuyn,
M. E. D., et al. (1998). Impairment of cognitive function in women receiving adjuvant
treatment for high-risk breast cancer: High-dose versus standard-dose chemotherapy.
Journal of the National Cancer Institute, 90(3), 210–218.
Vearncombe, K. J., Rolfe, M., Wright, M., Pachana, N. A., Andrew, B., & Beadle, G. (2009).
Predictors of cognitive decline after chemotherapy in breast cancer patients. Journal
of the International Neuropsychological Society, 15(6), 951–962.
Wefel, J. S., Lenzi, R., Theriault, R. L., Davis, R. N., & Meyers, C. A. (2004). The cognitive
sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma Results of a prospective, randomized, longitudinal trial. Cancer, 100(11), 2292–2299.
Wefel, J. S., Saleeba, A. K., Buzdar, A. U., & Meyers, C. A. (2010). Acute and late onset
cognitive dysfunction associated with chemotherapy in women with breast cancer.
Cancer, 116(14), 3348–3356.
Whitney, K. A., Lysaker, P. H., Steiner, A. R., Hook, J. N., Estes, D. D., & Hanna, N. H.
(2008). Is"chemobrain" a transient state? A prospective pilot study among persons
with non-small cell lung cancer. Journal of Supportive Oncology, 6(7), 313–321.
Wieneke, M. H., & Dienst, E. R. (1995). Neuropsychological assessment of cognitivefunctioning following chemotherapy for breast-cancer. Psycho-Oncology, 4(1), 61–66.
Yoshikawa, E., Matsuoka, Y., Inagaki, M., Nakano, T., Akechi, T., Kobayakawa, M., et al.
(2005). No adverse effects of adjuvant chemotherapy on hippocampal volume in
Japanese breast cancer survivors. Breast Cancer Research and Treatment, 92(1), 81–
84.